C3 and Lymphadenopathy: Furthermore, suppressing lipid-associated ROS production in neutrophils by LPX-1 treatment in MRL/lpr mice effectively attenuated disease progression, decreased production of autoantibodies and various inflammatory cytokines, increased serum C3 complement levels, and reduced the severity of splenomegaly, lymphadenopathy, and lupus nephritis.